Christine Sadlowski and Dr. Michael Williams talk to Dr. Pieter Sonneveld about the PERSEUS trial’s findings on subcutaneous daratumumab added to standard induction, consolidation, and maintenance therapy in transplant-eligible patients with multiple myeloma.